Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
November 2008

Metformin for Antipsychotic-Associated Weight Gain
Most studies with metformin (Avandamet and others) suggest that it attentuates weight gain or actually promotes weight loss in patients who are taking antipsychotics.

In Brief
Valproate Teratogenicity Increased by High Dose, Concomitant Drugs;Celecoxib, Naproxen Do Not Protect Against Alzheimer's Disease

Atomoxetine versus Methylphenidate for Pediatric ADHD
Methylphenidate (Ritalin and others) appears to be more efficacious than atomoxetine (Strattera) for treating attention-deficit/hyperactivity disorder in children but has more adverse effects.

Rivastigmine (Exelon) Patch
A transdermal system for delivering rivastigmine (Exelon) is now available in the United States for treating dementia associated with Alzheimer's or Parkinson's disease.

Atomoxetine versus Methylphenidate for Pediatric ADHD

November 2008

The selective norepinephrine reuptake inhibitor atomoxetine (Strattera) was approved by the US Food and Drug Administration (FDA) in 2002 for the treatment of attention-deficit/hyperactivity disorder (ADHD). How does it compare to older ADHD treatments, such as methylphenidate (Ritalin and others)?…

To view the rest of this article, please: